This article was originally published in The Tan Sheet
SmithKline Beecham to sell worldwide rights for the Rx antivirals Vectavir/Denavir (penciclovir) and Famvir (famciclovir) to Novartis for $1.63 bil. The deal is contingent upon FTC approval of the Glaxo SmithKline merger. Novartis will market the products with the antifungal Lamisil and its hormone replacement therapies. FDA rejected SB's attempted Rx-to-OTC switch of Denavir in 1999 and said in a March guidance it disfavors the use of such antiviral drugs in an OTC setting (1"The Tan Sheet" March 13, p. 3)
You may also be interested in...
The future of potential OTC antiviral treatments for herpes labialis, including Avanir Pharmaceuticals' docosanol 10% cream, is questionable in light of FDA's announcement that it disfavors use of such antiviral drugs in a nonprescription setting.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning